Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
1.
Hepatol Res ; 54(2): 201-212, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-37796562

RESUMEN

AIM: Metabolic dysfunction is a risk factor for esophageal squamous cell carcinoma (ESCC). We investigated the impact of the recently proposed metabolic dysfunction-associated fatty liver disease (MAFLD) and its subtypes on ESCC recurrence after endoscopic treatment. METHODS: This multicenter observational cohort study enrolled consecutive patients newly diagnosed with ESCC after endoscopic treatment. Patients were classified into MAFLD or non-MAFLD groups. The MAFLD group was further classified into non-obese and obese MAFLD groups with a body mass index cutoff value of 25 kg/m2 . The impact of MAFLD on the recurrence of ESCC was evaluated using a decision tree algorithm and random forest analysis. RESULTS: A total of 147 patients (average age 69 years; male : female, 127:20; observational period, 2.4 years) were enrolled. The 1-, 3-, and 5-year recurrence rates were 2.0%, 21.1%, and 33.7%, respectively. Independent risk factors for the recurrence of ESCC were MAFLD (HR 2.2812; 95% confidence interval 1.0497-4.9571; p = 0.0373), drinking status, and smoking status. Metabolic dysfunction-associated fatty liver disease was identified as the second most important classifier for recurrence, followed by drinking status. The cumulative incidence of ESCC recurrence was higher in the MAFLD group than in the non-MAFLD group. In a subanalysis, the cumulative incidence of recurrence was significantly higher in the non-obese than in the obese MAFLD group among abstainers/non-drinkers. Directed acyclic graphs revealed that MAFLD directly contributes to ESCC recurrence. CONCLUSIONS: MAFLD was independently and directly associated with ESCC recurrence after endoscopic treatment; a high recurrence rate was observed in patients with non-obese MAFLD. Metabolic dysfunction-associated fatty liver disease may identify patients at high risk for ESCC recurrence.

2.
Hepatol Res ; 54(6): 540-550, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38156966

RESUMEN

AIM: The incidence of Helicobacter pylori-negative gastric cancer (HPNGC) is increasing worldwide. Recently, metabolic dysfunction-associated fatty liver disease (MAFLD) has been reported to be associated with various cancers, but its association with HPNGC has not been reported. We aimed to identify important independent factors associated with HPNGC, including MAFLD. METHODS: This multicenter observational cohort study enrolled patients with gastric cancer (n = 1078) and health checkup examinees (n = 17 408). We analyzed patients with HPNGC (n = 26) and healthy participants with no H. pylori infection or any abnormal findings on upper gastrointestinal endoscopy (n = 1130). A logistic regression model was used to identify independent factors associated with HPNGC. The priority of the factors associated with HPNGC was evaluated using a decision-tree algorithm and random forest analysis. RESULTS: Among all patients with gastric cancer, 2.4% (26/1078) were diagnosed with HPNGC (mean age, 64 years; male/female, 13/13). In the logistic regression analysis, age, smoking, and MAFLD (odds ratio, 6.5359; 95% confidence interval, 2.5451-16.7841; p < 0.0001) were identified as independent factors associated with HPNGC. Metabolic dysfunction-associated fatty liver disease was also identified as the most important classifier for the presence of HPNGC in decision-tree analyses. Helicobacter pylori-negative gastric cancer was observed in 5.2% of patients with MAFLD and 0.8% of patients without MAFLD. In the random forest analysis of the HPNGC, MAFLD was identified as the distinguishing factor with the highest variable importance (0.32). CONCLUSIONS: Metabolic dysfunction-associated fatty liver disease was the most influential independent factor associated with HPNGC. These findings suggest that fatty liver and metabolic dysfunction could be involved in the pathogenesis of HPNGC.

3.
Int J Mol Sci ; 22(11)2021 May 22.
Artículo en Inglés | MEDLINE | ID: mdl-34067258

RESUMEN

Colorectal adenoma is linked to metabolic dysfunction. Metabolic dysfunction-associated fatty liver disease (MAFLD) has a precise definition and three subtypes, including non-obese MAFLD. We aimed to investigate the impact of MAFLD on the prevalence of colorectal adenoma by comparing it to non-alcoholic fatty liver disease (NAFLD) in health check-up examinees. This is a multicenter retrospective study. We enrolled 124 consecutive health check-up examinees who underwent colonoscopy. NAFLD and MAFLD were present in 58 and 63 examinees, respectively. Colorectal adenoma was diagnosed by biopsy. The impact of the MAFLD definition on the prevalence of colorectal adenoma was investigated by logistic regression, decision-tree, and random forest analyses. In logistic regression analysis, MAFLD was identified as the only independent factor associated with the presence of colorectal adenoma (OR 3.191; 95% CI 1.494-7.070; p = 0.003). MAFLD was also identified as the most important classifier for the presence of colorectal adenoma in decision-tree and random forest analyses (29 variable importance value). Among the three subtypes of MAFLD, non-obese MAFLD was the sole independent factor associated with the presence of colorectal adenoma (OR 3.351; 95% CI 1.589-7.262; p ≤ 0.001). Non-obese MAFLD was also the most important classifier for the presence of colorectal adenoma in decision-tree and random forest analyses (31 variable importance value). MAFLD, particularly non-obese MAFLD, is the most important factor associated with the presence of colorectal adenoma rather than NAFLD. Colonoscopy examination should be considered in patients with MAFLD, especially those who are non-obese.


Asunto(s)
Adenoma/etiología , Neoplasias Colorrectales/etiología , Enfermedad del Hígado Graso no Alcohólico/complicaciones , Adulto , Anciano , Anciano de 80 o más Años , Colonoscopía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Retrospectivos , Factores de Riesgo
5.
Bioorg Med Chem Lett ; 30(16): 127299, 2020 08 15.
Artículo en Inglés | MEDLINE | ID: mdl-32631519

RESUMEN

Inducing oligodendrocyte progenitor cell (OPC) differentiation is a novel therapeutic strategy for the treatment of demyelinating diseases such as multiple sclerosis (MS). In the preceding article, we detailed the discovery of compound 1, a potent inducer of OPC differentiation possessing a characteristic spiroindoline structure. Also, we found that N-methylation and des-carbonyl compound 1 (4) led to a loss in potency. Herein, we describe our investigations of a conformation-based hypothesis for OPC differentiation activity based on the preferred conformation of the spiro core, and further structure-activity relationship (SAR) exploration led to the identification of 6-CF3 derivative 8, which was more potent compared to compound 1.


Asunto(s)
Diseño de Fármacos , Indoles/farmacología , Células Precursoras de Oligodendrocitos/efectos de los fármacos , Compuestos de Espiro/farmacología , Animales , Diferenciación Celular , Relación Dosis-Respuesta a Droga , Indoles/síntesis química , Indoles/química , Estructura Molecular , Ratas , Compuestos de Espiro/síntesis química , Compuestos de Espiro/química , Relación Estructura-Actividad
6.
Bioorg Med Chem ; 28(6): 115348, 2020 03 15.
Artículo en Inglés | MEDLINE | ID: mdl-32046916

RESUMEN

A novel series of spiroindoline derivatives was discovered for use as inducers of oligodendrocyte progenitor cell (OPC) differentiation, resulting from optimization of screening hit 1. Exploration of structure-activity relationships led to compound 18, which showed improved potency (rOPC EC50 = 0.0032 µM). Furthermore, oral administration of compound 18 significantly decreased clinical severity in an experimental autoimmune encephalomyelitis (EAE) model.


Asunto(s)
Descubrimiento de Drogas , Encefalomielitis Autoinmune Experimental/tratamiento farmacológico , Indoles/farmacología , Células Precursoras de Oligodendrocitos/efectos de los fármacos , Compuestos de Espiro/farmacología , Animales , Diferenciación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Encefalomielitis Autoinmune Experimental/patología , Femenino , Indoles/síntesis química , Indoles/química , Ratones , Ratones Endogámicos C57BL , Estructura Molecular , Ratas , Ratas Wistar , Compuestos de Espiro/síntesis química , Compuestos de Espiro/química , Relación Estructura-Actividad
7.
World J Gastroenterol ; 24(42): 4809-4820, 2018 Nov 14.
Artículo en Inglés | MEDLINE | ID: mdl-30479467

RESUMEN

AIM: To determine the usefulness of assigning narrow-band imaging (NBI) scores for predicting tumor grade and invasion depth in colorectal tumors. METHODS: A total of 161 colorectal lesions were analyzed from 138 patients who underwent endoscopic or surgical resection after conventional colonoscopy and magnifying endoscopy with NBI. The relationships between the surface and vascular patterns of the lesions, as visualized with NBI, and the tumor grade and depth of submucosa (SM) invasion were determined histopathologically. Scores were assigned to distinct features of the surface microstructures of tubular and papillary-type lesions. Using a multivariate analysis, a model was developed for predicting the tumor grade and depth of invasion based on NBI-finding scores. RESULTS: NBI findings that correlated with a high tumor grade were associated with the "regular/irregular" (P < 0.0001) surface patterns and the "avascular area" pattern (P = 0.0600). The vascular patterns of "disrupted vessels" (P = 0.0714) and "thick vessels" (P = 0.0133) but none of the surface patterns were associated with a depth of invasion of ≥ 1000 µm. In our model, a total NBI-finding score ≥ 1 was indicative of a high tumor grade (sensitivity: 0.97; specificity: 0.24), and a total NBI-finding score ≥ 9 (sensitivity: 0.56; specificity: 1.0) was predictive of a SM invasion depth ≥ 1000 µm. Scores less than these cutoff values signified adenomas and a SM invasion depth < 1000 µm, respectively. Associations were also noted between selected NBI findings and tumor tissue architecture and histopathology. CONCLUSION: Our multivariate statistical model for predicting tumor grades and invasion depths from NBI-finding scores may help standardize the diagnosis of colorectal lesions and inform therapeutic strategies.


Asunto(s)
Neoplasias Colorrectales/diagnóstico por imagen , Modelos Estadísticos , Anciano , Colonoscopía/métodos , Neoplasias Colorrectales/patología , Neoplasias Colorrectales/cirugía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Imagen de Banda Estrecha/métodos , Clasificación del Tumor/métodos , Invasividad Neoplásica/patología , Estudios Retrospectivos , Sensibilidad y Especificidad
8.
Bioorg Med Chem Lett ; 28(12): 2222-2227, 2018 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-29752182

RESUMEN

In this study, we aimed to synthesize a novel blocker of transient receptor potential canonical 6 (TRPC6). The sp2 carbon atoms of the aminoindane skeleton of the known inhibitor were replaced with sp3 carbon atoms to increase the molecular complexity, measured by fraction sp3 (Fsp3). The representative compound, a bicyclo[4.3.0]nonane derivative DS88790512, inhibited TRPC6 with an IC50 value of 11 nM. Notably, DS88790512 exhibited excellent selectivity against hERG and hNaV1.5 channels, and was identified as an orally bioavailable compound.


Asunto(s)
Bloqueadores de los Canales de Calcio/farmacología , Descubrimiento de Drogas , Indanos/farmacología , Canal Catiónico TRPC6/antagonistas & inhibidores , Administración Oral , Animales , Disponibilidad Biológica , Bloqueadores de los Canales de Calcio/administración & dosificación , Bloqueadores de los Canales de Calcio/química , Relación Dosis-Respuesta a Droga , Humanos , Indanos/administración & dosificación , Indanos/química , Ratones , Microsomas Hepáticos/química , Microsomas Hepáticos/metabolismo , Estructura Molecular , Relación Estructura-Actividad , Canal Catiónico TRPC6/metabolismo
9.
Nihon Rinsho ; 74(11): 1909-1916, 2016 11.
Artículo en Japonés | MEDLINE | ID: mdl-30550703

RESUMEN

Previous data shows that colorectal serrated lesions are precursor of carcinogenesis. It has been advancing even molecular biological analysis, SSA/P become microsatellite instability (MSI) positive colon cancers and TSA become microsatellite stable (MSS) positive colon cancers. It is observed that redness and double elevation in conventional endoscopy, CP type II (Sano classification) in the NBI endoscopy, type III pit pattern in magnifying endoscopy, if SSA/P have cytological dysplastic change. Especially, if SSA/P have cancerous change, CP type III and type V pit pattern are observed.


Asunto(s)
Neoplasias Colorrectales/patología , Neoplasias Colorrectales/metabolismo , Humanos , Inestabilidad de Microsatélites
10.
Bioorg Med Chem Lett ; 21(24): 7337-43, 2011 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-22044620

RESUMEN

We have optimized 2-aminomethylphenylamine derivative as a factor Xa inhibitor. Several polar functional groups were introduced in the central phenyl ring, and we focused on zwitter ionic compound showing continuous inhibitory activity in oral administration test. In vitro and oral activities were improved by optimization of S1 and S4 ligands. Incorporating the interaction with S1-ß pocket enhanced in vitro factor Xa inhibitory activity to less than 1 nM. Many zwitter ionic compounds showed long duration of action and potent inhibitory activity and high AUC values in oral administration tests to monkeys.


Asunto(s)
Anticoagulantes/química , Inhibidores del Factor Xa , Inhibidores de Serina Proteinasa/química , Administración Oral , Compuestos de Anilina/síntesis química , Compuestos de Anilina/química , Compuestos de Anilina/farmacocinética , Animales , Anticoagulantes/síntesis química , Anticoagulantes/farmacocinética , Sitios de Unión , Simulación por Computador , Factor Xa/metabolismo , Haplorrinos , Iones/química , Estructura Terciaria de Proteína , Inhibidores de Serina Proteinasa/síntesis química , Inhibidores de Serina Proteinasa/farmacocinética , Relación Estructura-Actividad
11.
Bioorg Med Chem Lett ; 21(7): 2133-40, 2011 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-21345673

RESUMEN

We previously reported on a series of cyclohexanediamine derivatives as highly potent factor Xa inhibitors. Herein, we describe the modification of the spacer moiety to discover an alternative scaffold. Ethylenediamine derivatives possessing a substituent at the C1 position in S configuration and phenylenediamine derivatives possessing a substituent at the C5 position demonstrated moderate to strong anti-fXa activity. Further SAR studies led to the identification of compound 30 h which showed both good in vitro activity (fXa IC(50) = 2.2 nM, PTCT2 = 3.9 µM) and in vivo antithrombotic efficacy.


Asunto(s)
Inhibidores del Factor Xa , Inhibidores de Serina Proteinasa/química , Inhibidores de Serina Proteinasa/farmacología , Cristalografía por Rayos X , Diseño de Fármacos , Modelos Moleculares , Inhibidores de Serina Proteinasa/síntesis química , Relación Estructura-Actividad
12.
Bioorg Med Chem ; 19(5): 1623-42, 2011 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-21316975

RESUMEN

We have been researching orally active factor Xa inhibitor for a long time. We explored the new diamine linker using effective ligands to obtain a new attractive original scaffold 2-aminomethylphenylamine derivative. Compound 1D showed very strong in vitro and in vivo factor Xa inhibitory activity, as well as favorable PK profiles in po administration to monkeys.


Asunto(s)
Compuestos de Anilina/química , Compuestos de Anilina/síntesis química , Inhibidores de Factor de Coagulación Sanguínea/síntesis química , Inhibidores del Factor Xa , Animales , Inhibidores de Factor de Coagulación Sanguínea/química , Cristalografía por Rayos X , Haplorrinos , Humanos , Concentración 50 Inhibidora , Ligandos , Estructura Molecular , Ratas
13.
Bioorg Med Chem ; 17(24): 8206-20, 2009 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-19884015

RESUMEN

A series of cis-1,2-diaminocyclohexane derivatives were synthesized with the aim of optimizing previously disclosed factor Xa (fXa) inhibitors. The exploration of 5-6 fused rings as alternative S1 moieties resulted in two compounds which demonstrated improved solubility and reduced food effect compared to the clinical candidate, compound A. Herein, we describe the synthesis and structure-activity relationship (SAR), together with the physicochemical properties and pharmacokinetic (PK) profiles of some prospective compounds.


Asunto(s)
Anticoagulantes/uso terapéutico , Antitrombina III/uso terapéutico , Ciclohexilaminas/uso terapéutico , Diseño de Fármacos , Administración Oral , Sitios de Unión , Unión Competitiva , Cristalografía por Rayos X , Humanos , Concentración 50 Inhibidora , Absorción Intestinal/efectos de los fármacos , Cinética , Estructura Molecular , Glicoproteínas de Membrana Plaquetaria , Conformación Proteica , Relación Estructura-Actividad
14.
Bioorg Med Chem ; 17(24): 8221-33, 2009 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-19900814

RESUMEN

A series of cis-1,2-diaminocyclohexane derivatives possessing a 6-6 fused ring for the S1 moiety were synthesized as novel factor Xa (fXa) inhibitors. The synthesis, structure-activity relationship (SAR), and physicochemical properties are reported herein, together with the discovery of compound 45c, which has potent anti-fXa activity, good physicochemical properties and pharmacokinetic (PK) profiles, including a reduced negative food effect.


Asunto(s)
Anticoagulantes/química , Ciclohexilaminas/química , Diseño de Fármacos , Anticoagulantes/farmacología , Antitrombina III/uso terapéutico , Sitios de Unión , Ciclohexilaminas/farmacología , Estructura Molecular , Unión Proteica , Relación Estructura-Actividad
15.
Bioorg Med Chem ; 17(3): 1193-206, 2009 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-19128974

RESUMEN

In the early 1990's, we reported on the low-molecular selective fXa inhibitor DX-9065a having two amidino groups. However, it had poor oral bioavailability due to its strong basic amidino groups. To obtain fXa inhibitors with improved oral bioavailability, we investigated various non-amidino fXa inhibitors and finally discovered cis-1,2-diaminocyclohexane derivative 4c to have potent fXa inhibition, promising anticoagulant activity, and good oral bioavailability, compared with amidino compound DX-9065a. In addition, we will discuss the influence of the third substituent on the cyclohexane ring on anti-fXa activity, anticoagulant activity, PK profile, and lipophilicity.


Asunto(s)
Anticoagulantes/química , Anticoagulantes/farmacología , Inhibidores del Factor Xa , Indoles/farmacología , Propionatos/farmacología , Tiazoles/farmacología , Administración Oral , Animales , Anticoagulantes/síntesis química , Disponibilidad Biológica , Cristalografía por Rayos X , Factor Xa/metabolismo , Haplorrinos , Humanos , Indoles/química , Indoles/farmacocinética , Naftalenos/síntesis química , Naftalenos/química , Naftalenos/farmacología , Propionatos/síntesis química , Propionatos/química , Propionatos/farmacocinética , Unión Proteica , Tiazoles/química , Tiazoles/farmacocinética
16.
Bioorg Med Chem Lett ; 18(16): 4587-92, 2008 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-18675545

RESUMEN

There have been few reports on synthetic methods for cis-1,2-diaminocyclohexane bearing a third ring substituent. Starting from 3-cyclohexenecarboxylic acid, we developed efficient methods for synthesizing the 3,4-diaminocyclohexanecarboxylic acid derivatives 2-5. We also evaluated their anti-Xa and anticoagulant activities. Among the compounds, acid 2a and amide 2b exhibited the most potent in vitro anti-fXa activity, indicating that the position and stereochemistry of a polar functional group on the cyclohexane ring greatly affected the in vitro anti-fXa activity.


Asunto(s)
Benzotiazoles/síntesis química , Ácidos Carboxílicos/farmacología , Ciclohexilaminas/síntesis química , Inhibidores del Factor Xa , Animales , Anticoagulantes/farmacología , Antitrombina III/química , Antitrombina III/farmacología , Benzotiazoles/farmacología , Coagulación Sanguínea/efectos de los fármacos , Ácidos Carboxílicos/química , Química Farmacéutica/métodos , Ciclohexanos/química , Ciclohexilaminas/farmacología , Diseño de Fármacos , Factor Xa/química , Concentración 50 Inhibidora , Modelos Químicos , Inhibidores de Serina Proteinasa/síntesis química , Estereoisomerismo , Factores de Tiempo
17.
Bioorg Med Chem Lett ; 17(16): 4683-8, 2007 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-17555959

RESUMEN

This paper describes the synthesis of orally available potent fXa inhibitors 2 and 3 by modification of the piperazine part of lead compound 1. Carbonyl derivative 3 showed potent fXa activity but not sulfonyl derivative 2. Among the compounds synthesized, cyclohexane derivatives 3g and 3h and cycloheptane derivative 3j had potent anticoagulant activity as well as anti-fXa activity. Synthetic study of the optical isomers of 3g demonstrated that (-)-3g had more potent activity.


Asunto(s)
Anticoagulantes/química , Anticoagulantes/farmacología , Cicloparafinas/química , Cicloparafinas/farmacología , Inhibidores del Factor Xa , Animales , Disponibilidad Biológica , Diseño de Fármacos , Haplorrinos , Humanos , Microsomas Hepáticos , Estructura Molecular , Ratas , Relación Estructura-Actividad
18.
Bioorg Med Chem ; 14(5): 1309-30, 2006 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-16263291

RESUMEN

Serine protease factor xa (fXa) inhibitor 1 showed good ex vivo anti-fXa activity upon oral administration in rats. However, it has been revealed that 1 had low metabolic stability against human liver microsomes. To improve the metabolic stability, we attempted to modify the S1 and S4 ligands of 1. These modifications resulted in compound 34b, which exhibited selective anti-fXa activity and excellent anti-coagulation activity.


Asunto(s)
Anticoagulantes/farmacología , Antitrombina III , Coagulación Sanguínea/efectos de los fármacos , Péptidos/química , Inhibidores de Serina Proteinasa/farmacología , Administración Oral , Animales , Anticoagulantes/síntesis química , Antitrombina III/síntesis química , Antitrombina III/metabolismo , Antitrombina III/farmacología , Sitios de Unión , Pruebas de Coagulación Sanguínea , Relación Dosis-Respuesta a Droga , Diseño de Fármacos , Humanos , Ligandos , Microsomas Hepáticos/metabolismo , Péptidos/metabolismo , Ratas , Relación Estructura-Actividad
19.
Bioorg Med Chem ; 13(12): 3927-54, 2005 Jun 02.
Artículo en Inglés | MEDLINE | ID: mdl-15911309

RESUMEN

Compound 7 was identified as the active metabolite of 6 by HPLC and mass spectral analysis. Modification of lead compound 7 by transformation of its N-oxide 6-6 biaryl ring system and fused aromatics produced a series of non-basic fXa inhibitors with excellent potency in anti-fXa and anticoagulant assays. The optimized compounds 73b and 75b showed sub to one digit micromolar anticoagulant activity (PTCT2). Particularly, anti-fXa activity was detected in plasma of rats orally administered with 1mg/kg of compound 75b.


Asunto(s)
Anticoagulantes/síntesis química , Inhibidores del Factor Xa , Inhibidores de Serina Proteinasa/síntesis química , Inhibidores de Serina Proteinasa/farmacocinética , Administración Oral , Animales , Anticoagulantes/farmacología , Sitios de Unión , Coagulación Sanguínea/efectos de los fármacos , Pruebas de Coagulación Sanguínea , Diseño de Fármacos , Humanos , Absorción Intestinal , Ratas , Inhibidores de Serina Proteinasa/farmacología , Relación Estructura-Actividad
20.
Bioorg Med Chem ; 12(21): 5579-86, 2004 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-15465335

RESUMEN

Based on the both of results for X-ray studies of tetrahydrothiazolopyridine derivative 1c and FXV673, we synthesized a series of thiazol-5-ylpyridine derivatives containing pyridine N-oxide and 2-carbamoylthiazole units to optimize the S4 binding element. N-Oxidation of thiazol-5-ylpyridine increased the anti-fXa activity more than 10-fold independent on the position of N-oxide. The 4-pyridine N-oxide derivatives 3a and 3d excelled over the tetrahydrothiazolopyridine 1b in potency. 2-Methylpyridine N-oxide 3d exhibited 49-fold selectivity over thrombin. Our modeling study proposed a binding mode that the pyridine N-oxide ring of 3a stuck into the "cation hole" , and the oxide anion of 3a occupied in the almost same space to that of FXV673. From observations of the SAR and modeling studies, we suggested the possibilities that the formation of hydrogen bond with the oxide anion in the "cation hole" and the affinity of cationic pyridine ring to S4 subsite were responsible for increase in anti-fXa activity.


Asunto(s)
Óxidos N-Cíclicos/síntesis química , Diseño de Fármacos , Inhibidores del Factor Xa , Piridinas/síntesis química , Inhibidores de Serina Proteinasa/síntesis química , Amidinas/síntesis química , Amidinas/farmacología , Animales , Sitios de Unión/fisiología , Óxidos N-Cíclicos/farmacología , Factor Xa/metabolismo , Humanos , Masculino , Piridinas/farmacología , Ratas , Ratas Wistar , Inhibidores de Serina Proteinasa/farmacología , Tiazoles/síntesis química , Tiazoles/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA